|
1
|
Meggio F and Pinna LA:
One-thousand-and-one substrates of protein kinase CK2? FASEB J.
17:349–368. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Raaf J, Bischoff N, Klopffleisch K, et al:
Interaction between CK2alpha and CK2beta, the subunits of protein
kinase CK2: thermodynamic contributions of key residues on the
CK2alpha surface. Biochemistry. 50:512–522. 2011. View Article : Google Scholar
|
|
3
|
Buchou T, Vernet M, Blond O, et al:
Disruption of the regulatory beta subunit of protein kinase CK2 in
mice leads to a cell-autonomous defect and early embryonic
lethality. Mol Cell Biol. 23:908–915. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ahmad KA, Wang G, Unger G, Slaton J and
Ahmed K: Protein kinase CK2 - a key suppressor of apoptosis. Adv
Enzyme Regul. 48:179–187. 2008. View Article : Google Scholar
|
|
5
|
Piazza FA, Ruzzene M, Gurrieri C, et al:
Multiple myeloma cell survival relies on high activity of protein
kinase CK2. Blood. 108:1698–1707. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Prudent R, Moucadel V, Nguyen CH, et al:
Antitumor activity of pyridocarbazole and benzopyridoindole
derivatives that inhibit protein kinase CK2. Cancer Res.
70:9865–9874. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dominguez I, Sonenshein GE and Seldin DC:
Protein kinase CK2 in health and disease: CK2 and its role in Wnt
and NF-kappaB signaling: linking development and cancer. Cell Mol
Life Sci. 66:1850–1857. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Duncan JS and Litchfield DW: Too much of a
good thing: the role of protein kinase CK2 in tumorigenesis and
prospects for therapeutic inhibition of CK2. Biochim Biophys Acta.
1784:33–47. 2008. View Article : Google Scholar
|
|
9
|
Guerra B: Protein kinase CK2 subunits are
positive regulators of AKT kinase. Int J Oncol. 28:685–693.
2006.PubMed/NCBI
|
|
10
|
Zhang S, Wang Y, Mao JH, et al: Inhibition
of CK2α down-regulates Hedgehog/Gli signaling leading to a
reduction of a stem-like side population in human lung cancer
cells. PLoS One. 7:e389962012. View Article : Google Scholar
|
|
11
|
Varjosalo M and Taipale J: Hedgehog:
functions and mechanisms. Genes Dev. 22:2454–2472. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ingham PW, Nakano Y and Seger C:
Mechanisms and functions of Hedgehog signalling across the metazoa.
Nat Rev Genet. 12:393–406. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ng JM and Curran T: The Hedgehog’s tale:
developing strategies for targeting cancer. Nat Rev Cancer.
11:493–501. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Takebe N, Harris PJ, Warren RQ and Ivy SP:
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog
pathways. Nature Rev Clin Oncol. 8:97–106. 2011. View Article : Google Scholar
|
|
15
|
Ruiz i Altaba A: Therapeutic inhibition of
Hedgehog-GLI signaling in cancer: epithelial, stromal, or stem cell
targets? Cancer Cell. 14:281–283. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kinzler KW, Bigner SH, Bigner DD, et al:
Identification of an amplified, highly expressed gene in a human
glioma. Science. 236:70–73. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Epstein EH: Basal cell carcinomas: attack
of the hedgehog. Nature Rev Cancer. 8:743–754. 2008. View Article : Google Scholar
|
|
18
|
Ciucci A, De Stefano I, Vellone VG, et al:
Expression of the glioma-associated oncogene homolog 1 (gli1) in
advanced serous ovarian cancer is associated with unfavorable
overall survival. PloS One. 8:e601452013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shukla S and Gupta S: Apigenin-induced
cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and
loss of cyclin D1 associated retinoblastoma dephosphorylation in
human prostate cancer cells. Cell Cycle. 6:1102–1114. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shukla S and Gupta S: Suppression of
constitutive and tumor necrosis factor alpha-induced nuclear factor
(NF)-kappaB activation and induction of apoptosis by apigenin in
human prostate carcinoma PC-3 cells: correlation with
down-regulation of NF-kappaB-responsive genes. Clin Cancer Res.
10:3169–3178. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen D, Landis-Piwowar KR, Chen MS and Dou
QP: Inhibition of proteasome activity by the dietary flavonoid
apigenin is associated with growth inhibition in cultured breast
cancer cells and xenografts. Breast Cancer Res. 9:R802007.
View Article : Google Scholar
|
|
22
|
Way TD, Kao MC and Lin JK: Degradation of
HER2/neu by apigenin induces apoptosis through cytochrome c release
and caspase-3 activation in HER2/neu-overexpressing breast cancer
cells. FEBS Lett. 579:145–152. 2005. View Article : Google Scholar
|
|
23
|
Feng X, Zhou Q, Liu C and Tao ML: Drug
screening study using glioma stem-like cells. Mol Med Rep.
6:1117–1120. 2012.PubMed/NCBI
|
|
24
|
Castellanos JA, Merchant NB and
Nagathihalli NS: Emerging targets in pancreatic cancer:
epithelial-mesenchymal transition and cancer stem cells. Onco
Targets Ther. 6:1261–1267. 2013.PubMed/NCBI
|
|
25
|
Bae KM, Su Z, Frye C, et al: Expression of
pluripotent stem cell reprogramming factors by prostate tumor
initiating cells. J Urol. 183:2045–2053. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jia H, Liu Y, Xia R, et al: Casein kinase
2 promotes Hedgehog signaling by regulating both smoothened and
Cubitus interruptus. J Biol Chem. 285:37218–37226. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Varjosalo M, Li SP and Taipale J:
Divergence of hedgehog signal transduction mechanism between
Drosophila and mammals. Dev Cell. 10:177–186. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huangfu D and Anderson KV: Signaling from
Smo to Ci/Gli: conservation and divergence of Hedgehog pathways
from Drosophila to vertebrates. Development. 133:3–14. 2006.
View Article : Google Scholar
|
|
29
|
Chen Y, Sasai N, Ma G, et al: Sonic
Hedgehog dependent phosphorylation by CK1alpha and GRK2 is required
for ciliary accumulation and activation of smoothened. PLoS Biol.
9:e10010832011. View Article : Google Scholar
|
|
30
|
Sarno S and Pinna LA: Protein kinase CK2
as a druggable target. Mol Biosyst. 4:889–894. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gao Y and Wang HY: Casein kinase 2 is
activated and essential for Wnt/beta-catenin signaling. J Biol
Chem. 281:18394–18400. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cozza G, Meggio F and Moro S: The dark
side of protein kinase CK2 inhibition. Curr Med Chem. 18:2867–2884.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cozza G, Bortolato A and Moro S: How
druggable is protein kinase CK2? Med Res Rev. 30:419–462. 2010.
View Article : Google Scholar
|
|
34
|
Pierre F, Chua PC, O’Brien SE, et al:
Pre-clinical characterization of CX-4945, a potent and selective
small molecule inhibitor of CK2 for the treatment of cancer. Mol
Cell Biochem. 356:37–43. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Perea SE, Baladron I, Garcia Y, et al:
CIGB-300, a synthetic peptide-based drug that targets the CK2
phosphoaceptor domain. Translational and clinical research. Mol
Cell Biochem. 356:45–50. 2011. View Article : Google Scholar : PubMed/NCBI
|
